Preclinical Data Highlighting Therapeutic Potential of EPI-7386 Presented at 2019 American Urological Association Annual Meeting
ESSA Pharma Inc. (EPIX)
Last essa pharma inc. earnings: 2/13 05:48 pm
Check Earnings Report
US:NASDAQ Investor Relations:
essapharma.com/investors
Company Research
Source: PR Newswire
HOUSTON, TX and VANCOUVER, May 4, 2019 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting. In an oral poster presentation, "A New Generation of N-terminal Domain Androgen Receptor Inhibitors in Castration-Resistant Prostate Cancer Models", a deeper preclinical characterization of EPI-7386 was presented. The studies demonstrate that, pre-clinically, EPI-7386: Displays similar in vitro IC50 potency compared to the 'lutamide class of antiandrogens in an in vitro androgen receptor (AR) inhibition assay. Shows in vitro activity in several enzalutamide-resistant prostate cancer cell models in which enzalutamide is resistant. Exhibits a favorable metabolic profile across three preclinical animal species, which suggests that
Show less
Read more
Impact Snapshot
Event Time:
EPIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPIX alerts
High impacting ESSA Pharma Inc. news events
Weekly update
A roundup of the hottest topics
EPIX
News
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferencePR Newswire
- ESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its Business [Yahoo! Finance]Yahoo! Finance
- ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSPR Newswire
- Thinking about buying stock in Adverum Biotechnologies, Roma Green Finance, Wah Fu Education, ESSA Pharma, or Science 37?PR Newswire
- ESSA Pharma Inc (EPIX) Reports Q1 Fiscal 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
EPIX
Earnings
- 2/13/24 - Beat
EPIX
Sec Filings
- 4/25/24 - Form 4
- 4/5/24 - Form 4
- 4/5/24 - Form S-8
- EPIX's page on the SEC website